Showing results (891-900 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|March 8, 2008
The safety of dopamine agonists in the treatment of Parkinson's diseaseUbaldo Bonuccelli, Roberto CeravoloExpert Opinion on Drug Safety|March 8, 2008
Anticancer therapy in patients with porphyrias: evidence todayAntoine Thiery-Vuillemin, Loic Chaigneau, Nadine Meaux-Ruault, et al.Expert Opinion on Drug Safety|May 9, 2008
Antidepressants use in pediatric populationsJessica L GörenExpert Opinion on Drug Safety|May 9, 2008
Safety of stavudine in the treatment of HIV infection with a special focus on resource-limited settingsAlain Makinson, Vincent Le Moing, Charles Kouanfack, et al.Expert Opinion on Drug Safety|May 9, 2008
Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agentsNenad Sarapa, Margaret R BrittoExpert Opinion on Drug Safety|January 31, 2025
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting systemXiaomeng Wang, Jimei Wang, Fang Liu, et al.Expert Opinion on Drug Safety|January 20, 2025
Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilanceZuyue Liao, Cheng Luo, Yinghua Huang, et al.Expert Opinion on Drug Safety|February 6, 2025
Post-marketing safety concerns with luspatercept: a disproportionality analysis of the FDA adverse event reporting systemJin-Feng Liu, Ying-Tao Bai, Yan-En Leng, et al.Expert Opinion on Drug Safety|February 8, 2025
Association of ocular adverse events with varenicline solution use: a population-based studyMoiz Lakhani, Angela T H Kwan, Anne Xuan-Lan Nguyen, et al.Expert Opinion on Drug Safety|January 28, 2025
Drug-Induced Thrombocytopenia Severity and Toxicity (DITPst): binary classification of drugs by human thrombocytopenia toxicityXiaolu Nie, Fang Hu, Xiaoling Cheng, et al.Pageof 282